Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Blood-Based Alzheimer’s Testing Platform Offers Rapid Results

By LabMedica International staff writers
Posted on 18 Jun 2026

Accurate identification of Alzheimer’s disease pathology often relies on cerebrospinal fluid analysis or positron emission tomography, which can be invasive, costly, and not widely accessible. More...

In primary care, more than 90% of patients with mild cognitive impairment remain undiagnosed or misdiagnosed, often missing opportunities for early intervention. A new system now enables laboratories to perform blood-based Alzheimer’s biomarker testing with a 17-minute turnaround, supported by independent European validation demonstrating high diagnostic performance.

Sysmex Europe SE (Hamburg, Germany) has introduced the HISCL automated immunoassay system for Alzheimer’s blood biomarker testing. The platform is available for laboratory use with a CE‑IVD–marked amyloid beta (Aβ) 42/40 ratio assay, and access to the HISCL p‑Tau217 assay under Research Use Only (RUO). Positioned as a fully automated and non‑invasive alternative to traditional cerebrospinal fluid (CSF) and positron emission tomography (PET) pathways, the system is supported by clinical data from independent research centers.

The HISCL platform is a random‑access automated immunoassay system designed to fit into existing laboratory workflows without dedicated Alzheimer’s testing infrastructure or specialist training. A standard venous blood draw is the only pre‑analytical requirement, and individual sample measurement is completed in 17 minutes. The system is intended to scale from major academic centers and memory clinics to district general hospital laboratories, enabling broad deployment within routine settings.

Independent European studies presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 and ADPD 2026 conferences confirmed the performance of the HISCL p-Tau217 RUO and Aβ42/40 ratio assays for identifying amyloid beta pathology. Validation studies conducted by the Neurochemistry Laboratory at Amsterdam UMC and the Sant Pau Memory Unit in Barcelona, using different patient populations and reference standards, demonstrated strong analytical and diagnostic performance.

Across studies, the HISCL p-Tau217 RUO and p-Tau217/Aβ42 assays consistently achieved area under the receiver operating characteristic curve (AUROC) values above 0.90, with results closely aligned to cerebrospinal fluid and positron emission tomography reference methods. These findings support the platform’s potential use as a first-line triage tool for Alzheimer’s-related amyloid pathology in both research and clinical settings.

The HISCL p-Tau217 assay kit is for research use only and has not been validated by the manufacturer for diagnostic use. By combining rapid turnaround, automated operation, and independently validated performance, the platform is intended to help address diagnostic gaps where invasive or resource-intensive methods limit timely assessment.

“For clinicians and laboratory teams working with patients with cognitive concerns, the diagnostic journey has often meant invasive and time-consuming procedures. The HISCL platform changes that. A blood draw and a 17-minute result that is both clinically meaningful and reproducible at scale – this is what we offer to hospitals, memory clinics and laboratories across EMEA.” said Alain Baverel, CEO, Sysmex Europe SE.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.